vs
Side-by-side financial comparison of LandBridge Co LLC (LB) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $56.8M, roughly 1.2× LandBridge Co LLC). LandBridge Co LLC runs the higher net margin — 14.2% vs -49.0%, a 63.2% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 55.6%). LandBridge Co LLC produced more free cash flow last quarter ($122.0M vs $-84.7M).
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
LB vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $56.8M | $70.6M |
| Net Profit | $8.1M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 60.0% | -56.7% |
| Net Margin | 14.2% | -49.0% |
| Revenue YoY | 55.6% | 81958.1% |
| Net Profit YoY | -83.7% | 54.9% |
| EPS (diluted) | $0.24 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $56.8M | — | ||
| Q3 25 | $50.8M | $70.6M | ||
| Q2 25 | $47.5M | — | ||
| Q1 25 | $44.0M | — | ||
| Q4 24 | $36.5M | — | ||
| Q3 24 | $28.5M | — | ||
| Q2 24 | $26.0M | — | ||
| Q1 24 | $19.0M | — |
| Q4 25 | $8.1M | — | ||
| Q3 25 | $8.1M | $-34.6M | ||
| Q2 25 | $7.5M | — | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $49.3M | — | ||
| Q3 24 | $2.7M | — | ||
| Q2 24 | $-57.7M | — | ||
| Q1 24 | $10.8M | — |
| Q4 25 | 60.0% | — | ||
| Q3 25 | 60.8% | -56.7% | ||
| Q2 25 | 60.0% | — | ||
| Q1 25 | 57.0% | — | ||
| Q4 24 | 49.4% | — | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | -197.4% | — | ||
| Q1 24 | 71.1% | — |
| Q4 25 | 14.2% | — | ||
| Q3 25 | 15.9% | -49.0% | ||
| Q2 25 | 15.8% | — | ||
| Q1 25 | 14.7% | — | ||
| Q4 24 | 135.2% | — | ||
| Q3 24 | 9.3% | — | ||
| Q2 24 | -222.1% | — | ||
| Q1 24 | 56.7% | — |
| Q4 25 | $0.24 | — | ||
| Q3 25 | $0.26 | — | ||
| Q2 25 | $0.24 | — | ||
| Q1 25 | $0.20 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.04 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $30.7M | $490.9M |
| Total DebtLower is stronger | $570.7M | — |
| Stockholders' EquityBook value | $340.3M | $503.0M |
| Total Assets | $1.4B | $577.1M |
| Debt / EquityLower = less leverage | 1.68× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.7M | — | ||
| Q3 25 | $28.3M | $490.9M | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $14.9M | — | ||
| Q4 24 | $37.0M | — | ||
| Q3 24 | $14.4M | — | ||
| Q2 24 | $24.6M | — | ||
| Q1 24 | — | — |
| Q4 25 | $570.7M | — | ||
| Q3 25 | $366.1M | — | ||
| Q2 25 | $370.9M | — | ||
| Q1 25 | $375.5M | — | ||
| Q4 24 | $385.5M | — | ||
| Q3 24 | $242.4M | — | ||
| Q2 24 | $360.8M | — | ||
| Q1 24 | — | — |
| Q4 25 | $340.3M | — | ||
| Q3 25 | $272.0M | $503.0M | ||
| Q2 25 | $266.4M | — | ||
| Q1 25 | $217.0M | — | ||
| Q4 24 | $211.8M | — | ||
| Q3 24 | $97.2M | — | ||
| Q2 24 | $296.4M | — | ||
| Q1 24 | $162.3M | — |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.1B | $577.1M | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $689.9M | — | ||
| Q2 24 | $710.5M | — | ||
| Q1 24 | — | — |
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.73× | — | ||
| Q4 24 | 1.82× | — | ||
| Q3 24 | 2.49× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $126.3M | $-84.6M |
| Free Cash FlowOCF − Capex | $122.0M | $-84.7M |
| FCF MarginFCF / Revenue | 214.9% | -120.1% |
| Capex IntensityCapex / Revenue | 7.5% | 0.2% |
| Cash ConversionOCF / Net Profit | 15.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | $207.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $126.3M | — | ||
| Q3 25 | $34.9M | $-84.6M | ||
| Q2 25 | $37.3M | — | ||
| Q1 25 | $15.9M | — | ||
| Q4 24 | $67.6M | — | ||
| Q3 24 | $7.5M | — | ||
| Q2 24 | $16.0M | — | ||
| Q1 24 | $17.2M | — |
| Q4 25 | $122.0M | — | ||
| Q3 25 | $33.7M | $-84.7M | ||
| Q2 25 | $36.1M | — | ||
| Q1 25 | $15.8M | — | ||
| Q4 24 | $66.7M | — | ||
| Q3 24 | $7.1M | — | ||
| Q2 24 | $15.7M | — | ||
| Q1 24 | $17.1M | — |
| Q4 25 | 214.9% | — | ||
| Q3 25 | 66.3% | -120.1% | ||
| Q2 25 | 75.9% | — | ||
| Q1 25 | 36.0% | — | ||
| Q4 24 | 182.6% | — | ||
| Q3 24 | 25.1% | — | ||
| Q2 24 | 60.4% | — | ||
| Q1 24 | 90.1% | — |
| Q4 25 | 7.5% | — | ||
| Q3 25 | 2.3% | 0.2% | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 0.5% | — |
| Q4 25 | 15.68× | — | ||
| Q3 25 | 4.31× | — | ||
| Q2 25 | 4.98× | — | ||
| Q1 25 | 2.46× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 2.80× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
